Sanford Burnham Prebys Medical Discovery Institute (SBP) has been chosen as a dedicated center for the Experimental Therapeutics (NExT) Program Chemical Biology Consortium (CBC), centered at the Frederick National Laboratory for Cancer Research.
Research led by scientists at SBP has identified a new regulator of immune responses. The opens the door for a new approach to modulating T cell responses to treat infections, autoimmune diseases, and cancer.
A study led by scientists at the Sanford Burnham Prebys Medical Discovery Institute (SBP) has identified a malicious form of ATF2, a protein that drives the formation of melanoma.
Discovery provides proof of principle for safe, targeted delivery of drugs to the placenta to improve pregnancy outcomes
Academic-industry alliance seeks to find and validate new targets for drug development.
New research identifies a human (host) protein that weakens the immune response to HIV and other viruses. The findings, published in Cell Host & Microbe, have implications for improving HIV antiviral therapies and vaccines.
Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have shown that the protein complex mTORC1 is required for conversion of “bad” white fat to “good” brown fat. The findings, published online in the Journal of Clinical Investigation, could help treat metabolic disorders such as obesity.
Researchers at SBP have identified a new combination therapy for the most aggressive form of medulloblastoma, a fast growing pediatric brain cancer. These results are expected to lead to a clinical trial.
New research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a protein that can extend the natural lifespan of C. elegans, a microscopic roundworm commonly used for research on aging and longevity. The findings, published today in Cell Reports, expand what we know about the aging process and may lead to new ways to delay the onset of human age-related diseases such as cancer and neurodegenerative diseases.
SBP researchers have identified specific ways in which fetal muscle stem cells remodel their environment to support their enhanced capacity for regeneration, which could lead to targets for therapies to improve adult stem cells’ ability to replace injured or degenerated muscle.
Research from SBP Medical Discovery Institute suggests a new approach to treating metabolic disorders, including type 2 diabetes-- targeting the pathway that controls the concentration of certain heart hormones in the blood.
Marcia I. Dawson, whose pioneering research helped lay the groundwork for pro-apoptotic (programmed cell death) small molecules for the treatment of cancer, died recently at her home in Menlo Park, California.
Findings clear path to devise new treatments for muscular injuries and dystrophies
Seven-year award will support Ze’ev Ronai’s research on tumor adaptations to survive harsh conditions
Findings suggest a new approach to treat early heart failure
Search for new inflammatory disease drugs may be aided by detailed structure of distinct ubiquitin ligase complex
Letizia Amadini-Lane takes key position at SBP
Team of scientists from the Icahn School of Medicine at Mount Sinai and Sanford Burnham Prebys Medical Discovery Institute among those who combined large genomic and proteomic datasets to identify novel host targets to treat flu
Dietary fucose supplementation found to suppress the growth of melanoma
The first-in-class compound halts tumor growth by disrupting protein production
Doug Lewandowski will deepen the Institute’s cardiovascular disease expertise and direct Cardiovascular Translational Research.
SBP researchers combine publicly available cancer databases to identify new genes associated with cancer
SBP researchers and colleagues discover a mechanism that regulates the aging and abundance of secreted proteins
An emerging class of drugs called Smac mimetics may lead to a safe and effective treatment to eradicate HIV.
The appoptosin protein initiates a path that leads to the accumulation of tau, a key component of brain lesions.
The findings introduce new drug targets to selectively inhibit a key event in tumor cell progression.
In a collaborative study between Sanford Burnham Prebys Medical Discovery Institute (SBP) and the Argonne National Laboratory, scientists have used a highly specialized X-ray crystallography technique to solve the protein structure of hypoxia-inducible factors (HIFs), important regulators of a tumor’s response to low oxygen (hyopoxia).
Sanford Burnham Prebys Medical Discovery Institute’s Graduate School of Biomedical Sciences receives WASC accreditation
Study suggests that drugs targeting the lymphotoxin-beta receptor may improve liver cancer treatment.
Sanford Burnham Prebys Medical Discovery Institute (SBP) at Lake Nona today announced that the first funded company established based on work emerging from SBP’s Orlando campus, micro-gRx Incorporated, has received a $200,000 award from Space Florida through the Florida – Israel Innovation Partnership Program.
Sanford-Burnham Medical Research Institute announced today that it has received a gift of $100 million from prominent San Diego philanthropist Conrad Prebys. This is the largest donation ever made by Prebys and will be used to further implement the Institute’s 10-year strategic vision.
In a scientific discovery that has significant implications for preventing HIV infections, researchers at Sanford-Burnham Medical Research Institute have identified a protein that could improve the body’s immune response to HIV vaccines and prevent transmission of the virus.
Study explains why some melanoma tumors are resistant to BRAF inhibitor treatment
Sanford-Burnham Medical Research Institute at Lake Nona (Sanford-Burnham) today announced it has signed a two-year partnership agreement with Takeda Pharmaceutical Company Ltd. (Takeda) of Japan to study the potential role of several gene regulatory proteins as targets for the treatment of heart failure.
Sanford-Burnham Medical Research Institute (Sanford-Burnham) today announced the election of two new members to its Board of Trustees. The Board will grow to 23 members with the addition of the following new Trustees:
Scientists find a novel avenue for therapeutic intervention of the “silent cancer.”
Sanford-Burnham Medical Research Institute (Sanford-Burnham) today announced that it has signed a licensing agreement to further develop a first-in-class small molecule with Daiichi Sankyo for the treatment of cardiovascular-metabolic disease. The small molecule is based on longstanding, groundbreaking biology work by a Sanford-Burnham scientist and his laboratory team, who for decades focused their research on treating a consequence of cardiovascular-metabolic disease.
Researchers identify a control mechanism for glutamine uptake in breast cancer cells and its importance for response to select chemotherapies.
Sanford-Burnham Medical Research Institute at Lake Nona today announced that Michael Ayers has joined the Institute as associate director of Government Relations. In this role, he will develop and execute strategies to fortify Sanford-Burnham’s leadership role within Florida’s emerging life-sciences industry. Michael’s scope of responsibilities includes working with the Florida legislature, U.S. Congress, as well as state and federal government agencies to advance the Institute’s mission at its Lake Nona campus. Ayers will report to the vice president of Public Affairs.
Researchers find that melanoma cells are dependent on a source of glutamine for growth irrespective of the mutation(s) that drive the cancer.
Researchers identify signaling molecules in intestinal stem cells that can lead to tumors if left unregulated. The findings suggest a new approach to targeting intestinal cancers.
In a new study from Sanford-Burnham Medical Research Institute, researchers have used human pluripotent stem cells to generate new hair. The study represents the first step toward the development of a cell-based treatment for people with hair loss. In the United States alone, more than 40 million men and 21 million women are affected by hair loss. The research was published online in PLOS One yesterday.
Erkki Ruoslahti and Kristiina Vuori have been named NAI Fellows—a professional distinction accorded to academic inventors who have demonstrated a prolific spirit of innovation.
Researchers discover that moderate exercise following bariatric surgery reduces specific metabolic risk factors associated with type 2 diabetes. The findings suggest that moderate exercise may provide additional benefits to health beyond weight loss in these patients.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right